This narrative review identifies and critically examines the multifaceted challenges confronting the evidence-based application of exercise therapy in contemporary osteoporosis care and underscores that exercise must be conceptualized as a lifelong behavior rather than a time-limited intervention.
Abstract
Osteoporosis is a chronic, progressive bone condition that impacts over 200 million people globally, with fragility fractures significantly burdening healthcare systems and diminishing patient quality of life. Exercise is universally recommended as a foundational non-pharmacological intervention for osteoporosis management; however, a persistent translational gap separates the efficacy demonstrated in controlled trials from the outcomes observed in real-world clinical practice. This narrative review identifies and critically examines the multifaceted challenges confronting the evidence-based application of exercise therapy in contemporary osteoporosis care. Seven principal interrelated dilemmas are elucidated: the surrogate endpoint dependency on bone mineral density (BMD) rather than fracture incidence, profound heterogeneity of osteogenic effects across exercise modalities, the tension between effective osteogenic thresholds (≥70% 1RM) and safety concerns in high-risk subgroups, the absence of validated patient stratification tools, poor real-world adherence amid scarce supervised infrastructure and fragmented care pathways, pervasive nutritional inadequacies that undermine the skeletal response to mechanical loading, and methodologically heterogeneous evidence for traditional mind-body exercises that limits their equivalence to progressive resistance training. The reversibility of bone gains upon detraining further underscores that exercise must be conceptualized as a lifelong behavior rather than a time-limited intervention. Future priorities include fracture-powered pragmatic trials, validated osteoporosis-specific pre-exercise risk stratification instruments, implementation science addressing behavioral and systemic barriers, and integrated multidisciplinary care models that unite exercise professionals with bone specialists and dietitians. Until such evidence matures, clinicians must navigate a landscape of conditional recommendations, individualized risk-benefit assessments, and honest communication of uncertainty to patients.
Background/Objectives: Bone mineral density (BMD) is fundamental to osteoporosis assessment, but fracture risk is also shaped by fracture history, falls, frailty, secondary causes, age, sex, and treatment context. This narrative review examines clinically relevant information that modifies adult endocrine decision-maki...
L. Georgescu, Andreea Igna, Emilia Cristina Popa Tăut et al.· Journal of Clinical Medicine· 0 citations
This review synthesizes international guidelines and recent literature to provide a practical framework for DEXA interpretation, laboratory integration, and holistic management aimed at reducing refracture risk, improving functional outcomes, and lowering healthcare costs.
Jee-Young Lee, Se Lim Kim, G. Kong· Hip & Pelvis· 0 citations
Osteoporosis is one of the most common musculoskeletal disorders in older adults, associated not only with an increased risk of fractures but also with chronic pain, progressive disability, and a substantial economic burden on healthcare systems. The pathogenesis of chronic pain in osteoporosis is still predominantly v...
J. A. Bogdanova, R. Nurlygayanov, V. A. Kataev et al.· Bulletin of the Russian asso...· 0 citations
This narrative review synthesizes current evidence supporting osteosarcopenia as an integrated musculoskeletal syndrome, with a particular focus on biomechanical loading, biochemical crosstalk, and inflammatory signaling.
Jeonghyeon Seo, Sang Hoon Hwang, J. Yoon et al.· Journal of Korean Neurosurgi...· 0 citations
BACKGROUND
Osteoporosis and fragility fractures are major causes of disability, loss of independence, institutionalization, and mortality in the oldest old. Despite their exceptionally high fracture risk, adults aged ≥80 years remain underrepresented in randomized controlled trials. Diagnosis and treatment are complica...
H. Dimai, Barbara M. Obermayer-Pietsch· Gerontology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.